Weight Loss Medications

Understanding Weight Loss Drugs

Weight loss drugs have advanced significantly in recent years as obesity and metabolic health concerns continue to affect individuals throughout Sarasota and across Florida. In the United States, more than 40% of adults meet criteria for obesity, and an even greater percentage are overweight. Southern states, including Florida, are among the regions with the highest rates.

Despite the scale of the problem, only a small fraction of more than half of eligible individuals receive prescription weight loss medication, highlighting a significant gap between need and treatment. This gap reflects a combination of limited clinician familiarity with prescribing guidelines, concerns about medication safety, and barriers to insurance coverage.

Beyond supporting weight reduction, these medications can play a meaningful role in improving health outcomes. In many cases, they contribute to better control of conditions such as type 2 diabetes, cardiovascular disease, sleep apnea, fatty liver disease, and metabolic dysfunction.

At Solstice Health & Wellness, we combine medication, nutrition, physical activity, sleep, and behavioral support strategies in an integrated medical weight-loss program.

Weight management often intersects with stress, mental health, sleep, substance use, emotional eating, and overall lifestyle health. Therefore, treatment plans focus on the whole person rather than weight alone.

GLP-1 & Incretin-Based Weight Loss Medications

GLP-1 and incretin-based therapies work by mimicking natural gut hormones involved in appetite and metabolic regulation. As a result, they help reduce hunger, delay stomach emptying, improve insulin signaling, and support meaningful weight loss.

Shared GLP-1 Side Effects: Nausea, constipation, diarrhea, vomiting, bloating, stomach discomfort, acid reflux, gas, headache, fatigue, and dizziness. Importantly, most side effects occur during dose escalation and tend to improve over time.

Shared Contraindications (CI) / Precautions: People with a personal or family history of medullary thyroid cancer (MTC) or MEN2, or those with a serious allergy to the specific medication.

In addition, people with severe gastroparesis, a history of pancreatitis, gallbladder disease, kidney problems, or diabetic eye disease may need to avoid this medication. Please tell your doctor if you are pregnant, planning pregnancy, or breastfeeding.

Ultimately, the shared side effects, CI, and precautions above apply to all four GLP-1 medications below. Refer to the specific information listed under each medication.

Appetite & Craving Control Drugs

These medications primarily affect brain pathways involved in appetite, cravings, reward, emotional eating, and impulse control. In addition, several therapies influence pathways linked to compulsive eating behaviors and addiction.

Fat Absorption Weight Loss Drugs

Unlike most prescription weight loss medications, fat absorption therapies work within the digestive tract rather than through appetite or brain signaling pathways. They specifically reduce dietary fat absorption.

Choosing the Right Weight Loss Drug

The most appropriate weight loss medication depends on several factors, including medical history, metabolic health, eating behaviors, co-occurring conditions, lifestyle goals, medication cost, and tolerance for side effects.

Certain medications may interact with psychiatric medications, diabetes medications, seizure medications, opioids, or hormonal contraceptives. In addition, conditions such as pregnancy, eating disorders, pancreatitis history, cardiovascular disease, and substance use disorders may affect which medications are safe to use.

A comprehensive medical evaluation can help determine which treatment option may offer the safest, most effective, and most sustainable results.

Weight Loss Supplements: What You Should Know

Dietary supplements marketed for weight loss are widely available over the counter and do not require a prescription. However, unlike prescription weight loss medications, supplements are not required to prove they work before being sold.

The FDA does not evaluate supplements for effectiveness, nor does it require manufacturers to demonstrate consistent quality between batches. In fact, some products contain inaccurate ingredient amounts or undisclosed additives, including banned substances.

Most supplements produce only modest weight loss, typically 1 to 2 kg (about 2 to 4 pounds) more than placebo. As a result, they fall well below the threshold considered clinically meaningful.

Although some supplements may support a broader weight management plan, they cannot replace prescription medications, nutrition, physical activity, or behavioral support.

The supplements below have the most published research. However, we include them for educational purposes rather than as medical recommendations.

Fiber Supplements

Fiber supplements promote fullness by absorbing water and expanding in the stomach, which may reduce appetite and caloric intake. Some also slow digestion and help regulate blood sugar.

Thermogenic & Metabolic Supplements

Thermogenic and metabolic supplements may modestly increase energy expenditure, fat oxidation, or metabolic rate. Over time, however, their effects often diminish with regular use.

Fat & Body Composition Supplements

Supplements involved in body composition are thought to influence how the body stores, absorbs, or metabolizes dietary fat. Their effects on overall weight loss are small.

Gut Health & Nutrition Supplements

These supplements support weight management indirectly through effects on gut health, satiety, or body composition during calorie restriction. Rather than directly suppressing appetite or burning fat, they work through broader metabolic and nutritional pathways.

Why Does Weight Come Back After Stopping Medication?

Obesity is a chronic medical condition, similar to high blood pressure or high cholesterol, that often requires ongoing treatment.

When people stop weight loss medications, the body’s natural systems that regulate hunger, metabolism, and energy storage often push weight back toward its previous level. This can occur even when healthy eating and exercise habits continue.

Importantly, this is not a failure of willpower. Instead, it reflects the biology of obesity. As the body adapts to weight loss, it increases appetite hormones and slows metabolism. Consequently, many people regain weight after medication support ends.

Here’s What the Research Shows?

Studies consistently show that weight regain begins soon after stopping medication and is proportional to the amount of weight originally lost:

• Semaglutide (Wegovy): In the STEP 1 extension study, participants who lost an average of 17% of their body weight regained approximately two-thirds of that weight within one year of stopping the medication. Improvements in blood pressure, blood sugar, and cholesterol also reversed.
• Tirzepatide (Zepbound): In the SURMOUNT-4 trial, participants who stopped tirzepatide after losing about 21% of their body weight regained an average of 14% over the following year. Those who continued the medication lost an additional 5.5%, meaning the difference between continuing and stopping was nearly 20 percentage points.
• Liraglutide (Saxenda): Although people often regain weight after stopping liraglutide, the amount is smaller (about 4 lbs on average) because initial weight loss is more modest.
• Non-GLP-1 medications (Contrave, Qsymia, phentermine, orlistat): Weight regain also occurs after stopping these medications, though less data is available from formal withdrawal trials.

The key takeaway: weight regain after stopping medication is the expected biological response, not an exception.

Does This Mean I Have to Take Medication Forever?

Not necessarily, but it is important to have realistic expectations. Current medical guidelines recommend the following approach:

• In general, long-term use is recommended when medications are effective and well-tolerated. This is the most reliable way to maintain weight loss and its health benefits.
• Alternatively, some patients may prefer dose reduction strategies. Patients can maintain their weight loss on a lower dose than initially needed. Dose reduction can also reduce side effects and cost.
• If stopping medication is preferred or necessary, work closely with your healthcare provider to:
  – Taper gradually (do not stop suddenly, especially Qsymia)
  – Increase physical activity to at least 60 minutes per day
  – Follow a structured eating plan emphasizing whole, minimally processed foods
  – Monitor weight regularly (weekly self-weighing)
  – Return promptly if weight begins to increase significantly
• Consider intermittent or cyclical use. Some providers use a strategy of periodic medication courses rather than continuous treatment, though this approach has not been well studied in clinical trials.

What Can Help Maintain Weight Loss Long-Term?

Weight loss medications can be powerful tools in improving overall health. However, their effectiveness is greatest when combined with long-term nutrition, physical activity, sleep optimization, and sustainable lifestyle changes.

Incorporating weight loss medications with healthy habits leads to more sustainable results. Whether continuing medication or not, the following strategies are associated with better long-term weight maintenance.

Physical Activity

• Aim for at least 200–300 minutes per week of moderate activity (such as brisk walking) for weight maintenance. This is more than the 150 minutes recommended for general health.
• Include resistance training 2–3 times per week to preserve muscle mass, which is especially important after significant weight loss.

Nutrition

• Focus on whole, minimally processed foods: vegetables, fruits, lean proteins, whole grains, legumes, nuts, and seeds.
• Reduce or eliminate sugar-sweetened beverages and ultraprocessed foods.
• Practice portion control and consistent meal timing.
• A daily multivitamin may be helpful, especially if appetite remains reduced.

Behavioral Support

• Regular self-weighing (at least weekly) helps catch early weight regain.
• Ongoing behavioral counseling, support groups, or structured programs improve long-term outcomes.
• Address sleep quality (aim for 7–9 hours), stress management, and emotional eating patterns.

Medical Follow-Up

• Schedule regular check-ins with your healthcare provider, at least every 3 months after reaching your weight goal.
• If weight regain exceeds 3–5% of your lowest weight, discuss restarting or adjusting medication promptly rather than waiting for full regain.
• Review all medications with your provider, as some common prescriptions (certain antidepressants, diabetes medications, steroids) can promote weight gain.

Important Reminders

• Stopping weight loss medication is not recommended simply because your weight has reached a “normal” BMI. Just as blood pressure medication is not stopped when blood pressure normalizes, weight loss medication may need to continue to maintain its benefits.
• If cost or access is a barrier to continuing medication, talk to your provider about lower-cost alternatives, dose reduction strategies, or manufacturer savings programs.
• Weight management is a long-term journey. Small amounts of weight regain are normal and do not mean treatment has failed. Early intervention is key to preventing larger regain.

The Psychological Impact: Mental Health and Self-Esteem

Weight loss can affect mental and emotional well-being in several ways. For many individuals, successful weight loss is associated with improved self-esteem, physical functioning, quality of life, and reduced depressive symptoms.

However, the relationship between weight loss medications and mental health varies by medication class. GLP-1 receptor agonists have demonstrated improvements in mental health-related quality of life in clinical trials. In contrast, certain medications, including topiramate-containing therapies and naltrexone-bupropion, may contribute to mood changes, anxiety, or depression in some individuals.

Because emotional health plays an important role in long-term success, weight management plans should also address mental health, stress, sleep, and behavioral factors.

Weight Loss Medications in Addiction Recovery

Emerging research suggests that some weight loss medications may benefit individuals with co-occurring substance use disorders (SUDs). This overlap likely reflects shared brain pathways involved in appetite, reward, cravings, and metabolic regulation.

Healthcare providers currently prescribe anti-obesity medications off-label for SUD-related indications, while clinical trials are ongoing.

GLP-1 Receptor Agonists

GLP-1 receptor agonists such as semaglutide and liraglutide currently have the strongest emerging evidence in addiction recovery research. For example, a 2026 randomized controlled trial found that semaglutide significantly reduced alcohol consumption in treatment-seeking individuals with alcohol use disorder and obesity.

Large observational studies have also linked GLP-1 receptor agonists with lower rates of alcohol, nicotine, cannabis, cocaine, and opioid-related disorders, along with reduced SUD-related hospitalizations and mortality. However, research outside alcohol use disorder remains early, and additional clinical trials are ongoing.

Naltrexone-Bupropion

Naltrexone-bupropion may offer added benefit for some individuals with obesity and co-occurring SUDs. The combination of injectable naltrexone and oral bupropion has shown benefit for methamphetamine use disorder, and ASAM/AAAP recently included it in guidelines for amphetamine-type stimulant use disorder.

Healthcare providers may also consider the oral Contrave formulation for heavier individuals with depression, nicotine dependence, or alcohol use concerns.

Topiramate

Topiramate, prescribed as monotherapy rather than as part of the phentermine-topiramate combination (Qsymia), has evidence across several conditions relevant to individuals with co-occurring obesity and SUDs.

It has the strongest evidence for alcohol use disorder, and VA/DoD and APA guidelines recommend it as a first- or second-line treatment. Furthermore, topiramate has conditional guideline recommendations for cocaine and methamphetamine use disorders, along with preliminary evidence for smoking cessation.

Topiramate may also reduce excessive eating and purging behaviors in binge eating disorder and bulimia nervosa while simultaneously promoting weight loss. As a result, it may offer a uniquely versatile option for individuals with overlapping eating disorders, obesity, and SUDs.

Although the FDA has not approved topiramate as a standalone weight loss medication, healthcare providers widely prescribe it off-label for weight management.

The Future of Weight Loss Medications: Research and Innovation

The future of weight loss medications is promising, with ongoing research driving innovation. New discoveries are focusing on more effective and safer options to aid weight management.

New Trends in the Field

• Triple-agonist therapies approaching weight loss levels previously seen only with bariatric surgery
• Oral formulations that eliminate the need for injections, improving access and patient preference
• Monthly or less frequent dosing options to improve adherence
• Enhanced understanding of how combining different hormonal pathways can optimize weight loss and metabolic health

Weight Loss Medications in the Pipeline

Researchers are evaluating several promising agents in late-stage clinical trials:

• Retatrutide: A triple GIP/GLP-1/glucagon receptor agonist that demonstrated weight loss of approximately 24% at 48 weeks on the 12 mg dose. This is the highest reported for any anti-obesity medication in clinical trials.
• CagriSema: A combination of semaglutide and cagrilintide that achieved average weight loss of 20.4% at 68 weeks, with over 40% of fully adherent participants achieving 25% or greater weight reduction.
• Survodutide: A dual GLP-1/glucagon receptor agonist that achieved 14.9% weight loss at 46 weeks in a phase 2 trial.
• MariTide (maridebart cafraglutide): A monthly injectable monoclonal antibody that inhibits the GIP receptor and is conjugated with GLP-1 analogue peptides. It achieved 16.2% weight loss at 52 weeks, with monthly or less frequent dosing.

These investigational therapies may expand future treatment options by improving effectiveness, convenience, and long-term weight management outcomes.

Weight Loss Medication Treatment in Sarasota, FL

At Solstice Health & Wellness in Sarasota, we help patients understand their weight loss medication options and determine which approach may be safest and most effective for their individual needs.

We deliver coordinated, comprehensive care that integrates addiction medicine, primary care, and mental health services. As a result, treatment extends beyond weight loss alone to address the medical, emotional, and lifestyle factors that influence long-term outcomes.

Our practice serves patients throughout Sarasota, Bradenton, Venice, and North Port along Florida’s Gulf Coast.

If you are considering prescription weight loss medication treatment in Sarasota, Florida, our team provides individualized, medically guided care to support your goals.

Ready to Explore Prescription Weight Loss Options?

Schedule a consultation with our Solstice Health & Wellness team in Sarasota to review your health history, discuss medication options, and create a personalized medical weight loss plan.

Call or connect with Solstice Health & Wellness in Sarasota today.

Frequently Asked Questions About Weight Loss Drugs